Treatment for lung cancer has advanced considerably over the years and has been accelerating at an even faster rate this past decade. People diagnosed with lung cancer today have newer, more personalized treatment options that may include targeted therapies, [...]
Question: "I’ve seen commercials for immunotherapy as a treatment for lung cancer. How does it work? How do I know if it’s a good treatment for me?" Answer: Immunotherapy is a type of cancer treatment that helps the body’s [...]
On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line [...]
On August 11th, 2022, the Food and Drug Administration (FDA) approved Enhertu (fam- trastuzumab deruxtecan-nxki) for treatment of advanced non-small cell lung cancer (NSCLC) with an activating HER2 mutation for patients who have received one prior line of therapy. [...]
Author: Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment [...]
Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for [...]
By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer Rebecca (KRAS driven stage 4 NSCLC patient) and Wayne Yeung (caregiver) Since the original publication of this article, the United States Food [...]
On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of [...]